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Abstract
Background: The expression of the drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is regulated by the 
pregnane × receptor (PXR), which is modulated by numerous signaling pathways, including the cyclin-dependent 
kinase (Cdk) pathway. Flavonoids, commonly consumed by humans as dietary constituents, have been shown to 
modulate various signaling pathways (e.g., inhibiting Cdks). Flavonoids have also been shown to induce CYPs 
expression, but the underlying mechanism of action is unknown. Here, we report the mechanism responsible for 
flavonoid-mediated PXR activation and CYP expression.
Results: In a cell-based screen designed to identify compounds that activate PXR-mediated CYP3A4 gene expression in 
HepG2 human carcinoma cells, we identified several flavonoids, such as luteolin and apigenin, as PXR activators. The 
flavonoids did not directly bind to PXR, suggesting that an alternative mechanism may be responsible for flavonoid-
mediated PXR activation. Consistent with the Cdk5-inhibitory effect of flavonoids, Cdk5 and p35 (a non-cyclin 
regulatory subunit required to activate Cdk5) were expressed in HepG2. The activation of Cdk5 attenuated PXR-
mediated CYP3A4 expression whereas its downregulation enhanced it. The Cdk5-mediated downregulation of CYP3A4 
promoter activity was restored by flavonoids, suggesting that flavonoids activate PXR by inactivating Cdk5. In vitro 
kinase assays showed that Cdk5 directly phosphorylates PXR. The Cdk kinase profiling assay showed that apigenin 
inhibits multiple Cdks, suggesting that several Cdks may be involved in activation of PXR by flavonoids.
Conclusions: Our results for the first time link the stimulatory effect of flavonoids on CYP expression to their inhibitory 
effect on Cdks, through a PXR-mediated mechanism. These results may have important implications on the 
pharmacokinetics of drugs co-administered with herbal remedy and herbal-drug interactions.
Background
The pregnane × receptor (PXR) is a key xenobiotic recep-
tor that regulates the metabolism and excretion of xeno-
biotics and endobiotics by regulating the expression of
drug-metabolizing enzymes and drug transporters [1,2].
Expression of PXR target gene is regulated by binding of
PXR to its promoter region, such as that of cytochrome
P450 3A4 (CYP3A4), a key enzyme that catalyzes the
metabolism of more than 50% of all clinically prescribed
drugs [3]. Changes in the expression of CYP3A4 affect
drug metabolism and alter the therapeutic and toxico-
logic responses to drugs, which may in turn lead to
adverse drug interactions.
The activity of PXR is regulated not only by direct
ligand binding [4] but also by various cell signaling path-
ways [5], such as those mediated by protein kinase C
(PKC) [6], protein kinase A (PKA) [7,8], cyclin-dependent
kinase 2 (Cdk2) [9], 70kDa form of ribosomal protein S6
kinase (p70 S6K) [10], forkhead in rhabdomyosarcoma
(FKHR) [11], and nuclear factor κB (NF-κB) [12-14].
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Flavonoids - secondary metabolites found ubiquitously
in plants - are the most common group of polyphenolic
compounds consumed by humans as dietary constituents
[15]. Thousands of naturally occurring flavonoids, such
as flavones and isoflavones, have been characterized [16].
Flavonoids have been reported to have anti-allergic, anti-
inflammatory, anti-microbial and anti-cancer activities
[17,18]. The widespread use of flavonoids, coupled with
their potentially beneficial effects, has triggered studies
on the mechanism by which they modulate signaling
pathways.
Natural flavonoids have been shown to inhibit Cdk1,
Cdk2 [19], and Cdk5 [20]. Most Cdks, including Cdk1
and Cdk2, are involved in cell cycle regulation and
require the binding of cyclins for their activation. How-
ever, the activation of Cdk5 requires one of the two non-
cyclin regulatory subunits p35 or p39, which have 57%
amino acid homology. p35 can be converted in a Ca2+-
dependent manner to p25, a highly active and stable pro-
teolytic product [21,22]. The protease calpain catalyzes
the cleavage of p35, and this reaction can be effectively
inhibited by specific inhibitors of calpain such as calpep-
tin [23,24]. Cdk5 is not involved in cell cycle progression,
and is expressed in all tissues, but its levels of expression
and activity are highest in the nervous system [21,25].
The expressions of p35 and p39 are also highest in the
nervous system. Although Cdk5 has been mainly impli-
cated in early development of the central nervous system
(CNS) and maintenance of neuronal architecture [21,26],
the expression and regulatory activity of Cdk5/p35 have
also been reported in several non-CNS tissues such as
lens epithelia [27], muscle tissues [28], hepatoma cells
[25], adipose tissues [29], and male reproductive system
[30].
The widespread use of flavonoids has triggered studies
to investigate their effects on drug metabolism and
herbal-drug interactions. Recently, flavonoids have been
shown to induce CYP expression through PXR [31-36],
but the mechanism of flavonoids-mediated PXR activa-
tion and CYP induction remain unknown.
Because the function of PXR can be modulated by cel-
lular signaling pathways, we used a cell-based screening
approach in this study to identify compounds with
known bioactivities that activate PXR-mediated gene
expression. By screening a library of known bioactive
compounds, we identified a series of flavonoids that are
PXR activators. Since these flavonoids did not directly
bind to PXR, and flavonoids might inhibit Cdk5, we stud-
ied the effect of flavonoids on the activity of Cdk5/p35
and the regulation of PXR by Cdk5 in order to determine
the possible role of flavonoids in regulating PXR-medi-
ated gene expression of CYP3A4.
Results
Flavonoids activate PXR-mediated CYP3A4 gene 
expression
By screening a library of 3200 compounds with known
bioactivity in the human carcinoma cell line HepG2 sta-
bly transfected with PXR and CYP3A4-luc, which was
previously used to detect the activation PXR [9], we iden-
tified a series of flavonoids as potent activators of PXR-
mediated CYP3A4 promoter activation (Fig. 1). These fla-
vonoids included flavones luteolin, apigenin (Fig. 1A),
and chrysin (Fig. 1B) and isoflavones daidzein, biochanin
A, prunetin, and genistein (Fig. 1B). Rifampicin, a human
PXR agonist, was used as a control in this assay, and had
an EC50 of 1.3 μM. Compared with the activation of PXR
by rifampicin at 2 μM (a concentration at which PXR is
activated without causing cytotoxicity), some flavonoids
were more potent at activating PXR at high concentra-
tions. For example, luteolin at 40 μM was 7 times more
effective than 2 μM rifampicin in activating PXR. Under
the same assay conditions and compound treatment time
(24 h) as the PXR transactivation assay described above,
no significant cytotoxicity was detected for all flavonoids
tested (data not shown).
To determine whether the flavonoids activate PXR by
d i r e c t l y  b i n d i n g  t o  i t ,  w e  t e s t e d  3  f l a v o n o i d s  ( c h ry s i n ,
luteolin, and apigenin) in a PXR-binding assay. Although
the potent PXR agonist SR-12813 bound strongly (Fig.
2A; IC50 = 42 nM) to PXR, chrysin did not bind to PXR at
all concentrations tested (Fig. 2A). Luteolin and apigenin
did not bind to PXR at or below 10 μM. However, below
10 μM, they strongly activated PXR (more than 50% of
the activity from 2 μM of rifampicin) (Fig. 1A). These
data suggest that mechanisms other than direct PXR
binding might be responsible for chrysin-, luteolin-and
apigenin-mediated PXR activation.
Activation of Cdk5/p35 attenuates PXR-mediated gene 
expression
Flavonoids have been shown to inhibit protein kinases,
including Cdks [19,20]. Flavonoids may regulate PXR by
inhibiting Cdk2, as Cdk2 has been shown to negatively
regulate PXR [9]. However, because flavonoids can
inhibit Cdk5 [20] and Cdk5/p35 signaling (which is not
regulated by cell cycling) is active in hepatoma [25], we
tested whether inhibition of Cdk5 by flavonoids is
responsible for the flavonoids-mediated activation of
PXR.
Since the activity of Cdk5 requires p35 as a critical reg-
ulatory subunit, we determined whether p35 is expressed
in HepG2 cells, in which flavonoid-mediated activation of
PXR was first discovered. We found that p35 was
expressed in HepG2 cells at levels comparable to those inDong et al. BMC Biochemistry 2010, 11:23
http://www.biomedcentral.com/1471-2091/11/23
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IMR-32 (Fig. 2B), a neuronal cell line that expresses p35
and has been used as a positive control for p35 expression
[25].
Next, we determined the functional correlation
between the activities of Cdk5 and PXR. Overexpression
of Cdk5 led to attenuation of both basal (DMSO control)
and rifampicin-induced activation of PXR (Fig. 3A).
Expression levels of PXR were not affected by overexpres-
sion of Cdk5 (Fig. 3B), confirming that the attenuation of
PXR activity is because of the inhibitory effect of Cdk5 on
PXR and not because of a decrease in expression level of
PXR. The inhibitory effect of Cdk5 on PXR was further
confirmed by the increase in PXR activity on siRNA-
mediated downregulation of Cdk5 (Fig. 3C). Reduced
Figure 1 Flavonoids activate PXR-mediated CYP3A4 gene expression. HepG2 cells (2 × 104/well) stably transfected with PXR and CYP3A4-luc [9] 
were seeded in 384-well plates and treated with indicated compounds for 24 h before the luciferase assay. CYP3A4 promoter activity induced by com-
pound was expressed as a percentage of activation (% Act) by normalizing with luciferase activity from 2 μM rifampicin. Compounds were tested at 
11 concentrations starting at 40 μM (leftmost for each compound), 1:1.5 (A) or 1:3 (B) serial dilutions. In (A), the concentrations for each compound 
tested were 40, 26.667, 17.778, 11.852, 7.901, 5.267, 3.512, 2.341, 1.561, 1.040 and 0.694 μM (from left to right). In (B), the concentrations for each com-
pound tested were 40, 13.333, 4.444, 1.481, 0.494, 0.165, 0.055, 0.018, 0.006, 0.002 and 0.0007 μM (from left to right). Compounds were tested in qua-
druplicate. The bars denote the standard deviation.
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expression of Cdk5 in response to siRNA treatment was
verified (Fig. 3D). In addition, we showed that flavonoids
significantly decreased the inhibitory effect of Cdk5 on
CYP3A4 promoter activity induced by rifampicin (Fig. 4).
In the absence of flavonoids, Cdk5 inhibited CYP3A4
promoter activity by 40%. The inhibitory effect of Cdk5
was decreased to 4% and 23% by 20 μM of biochanin A
and 20 μM of chrysin, respectively (Fig. 4B). These results
suggest that flavonoids may inhibit Cdk5 and restore the
Cdk5-mediated downregulation of CYP3A4  promoter
activity.
To further validate the role of Cdk5 in regulating PXR
function, we examined the effect of calpeptin on PXR
function. Calpeptin has been shown to block the conver-
sion of p35 to the highly active p25, thereby reducing the
activity of Cdk5 [23,24]. Therefore we anticipated that the
calpeptin-mediated inhibition of Cdk5 would lead to acti-
vation of PXR, and calpeptin may restore the Cdk5-medi-
ated downregulation of CYP3A4  promoter activity.
Indeed, we found that calpeptin induced PXR activity
(e.g., 4.4 μM of calpeptin is as potent as 2 μM of rifampi-
cin) (Fig. 1B), and significantly (p < 0.001) decreased the
inhibitory effect of Cdk5 on the activity of CYP3A4 pro-
moter (Fig. 4B). Taken together, these data indicate that
Cdk5 negatively regulates PXR activity, and that inhibi-
Figure 2 Chrysin, apigenin, and luteolin are not potent PXR binders; p35 is expressed in HepG2. (A) Chrysin, apigenin, and luteolin are not po-
tent PXR binders. SR12813, a potent human PXR agonist, was used as a positive control. Relative binding (%) was determined as described in Methods. 
Compounds were tested in triplicate. The bars denote the standard deviation. (B) p35 is expressed in HepG2 (lane 4). HEK 293T (293T) cells transfected 
with a p35 expression construct (293T/p35) (8 × 105 cells in 6-well plates transfected with 1 μg of pCMV-mycP35 using Fugene 6) was used as a positive 
control for p35 expression (lane 1). 293T was used as a negative control (lane 2). IMR-32, a neuroblastoma cell line that expresses p35 endogenously, 
was used as an additional positive control (lane 3). Total amount of lysate (μg) used is indicated above the samples. Since only 5 μg of total protein 
was used in lane 1, no actin band was detected.
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tion of Cdk5 is at least partially responsible for fla-
vonoids-induced activation of PXR.
Cdk5 phosphorylates PXR
One possible mechanism by which Cdk5 regulates PXR is
by directly phosphorylating PXR. All Cdks recognize the
same motif for phosphorylation, and Cdk2 [9] and Cdk1
[37] have been shown to phosphorylate PXR. As
expected, in an in vitro kinase assay, reconstituted com-
plexes of purified Cdk5/p35 directly phosphorylated PXR
(Fig. 5), suggesting that Cdk5 can directly phosphorylate
hPXR.
Inhibition of multiple Cdks might contribute to flavonoids-
mediated activation of PXR
Since flavonoids have been reported to inhibit multiple
Cdks, we investigated the inhibitory effect of flavonoid
apigenin on various Cdks. Apigenin inhibited multiple
Cdks, including Cdk2, 4, 5, 7, 8, 9 and 11 (Table 1). Since
Cdk2 has been previously shown to negatively regulate
PXR function [9], these data suggest that inhibition of
multiple Cdks might contribute to the activating effect of
flavonoids on PXR.
Discussion
The widespread use of flavonoids has triggered several
studies to investigate the molecular mechanisms of action
of these naturally occurring compounds. Flavonoids have
been reported to inhibit protein kinases such as Cdks [20]
and induce the expression of drug-metabolizing enzymes
such as CYPs [31-36]. The stimulatory effect of fla-
vonoids on CYP expression might have significant impli-
cation on the pharmacokinetics of drugs co-administered
with herbal remedy and potential herbal-drug interac-
tions.
In a cell-based screening approach designed to identify
activators of PXR, we identified that flavones luteolin,
apigenin and chrysin and isoflavones daidzein, biochanin
A, prunetin, and genistein are activators of PXR-medi-
Figure 3 Cdk5 activation attenuates PXR-mediated gene expression. (A) Overexpression of Cdk5 reduces PXR-mediated CYP3A4 promoter activ-
ity. HepG2 was transiently co-transfected with indicated plasmids as well as CMV-renilla luciferase plasmid (as a transfection control). In cases wherein 
Cdk5, FLAG-PXR, or CYP3A4-luc constructs were not used, a pcDNA3 vector was used instead. Equal amount of each plasmid (for a total of 1 μg com-
bined) was used to transfect 8 × 105 cells seeded in 6-well plates. Cells were treated with 5 μM rifampicin or DMSO for 24 h after transfection before 
Dual-glo luciferase assay. CYP3A4 promoter activity (expressed as relative luciferase unit, or RLU) was normalized by using activity of the CMV-renilla. 
The values represent the average of 8 independent experiments, with the standard deviation denoted as bars. The significance of the difference be-
tween datasets was determined by using the Student's t test. (B) Expression of PXR and Cdk5. Transfections were performed as described in (A). West-
ern blotting shown was from a representative experiment. (C) Downregulation of Cdk5 enhances the activity of PXR. HepG2 was transfected with 
siRNA specific for Cdk5 (siRNA-Cdk5) or control siRNA (siRNA-Control) in addition to indicated plasmids and CMV-renilla as described in Methods. Cells 
were treated with 5 μM rifampicin. CYP3A4 promoter activity was expressed as RLU as described in (A). The values represent the average of 6 indepen-
dent experiments. The efficiency of Cdk5 knockdown was verified in (D).
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ated  CYP3A4  gene expression. Genistein and daidzein
have been previously reported to activate PXR [35]. In
our study, the lack of potent binding of chrysin, luteolin
and apigenin to PXR suggests that mechanisms other
than direct PXR binding might be responsible for PXR
activation by these flavonoids, and the reported inhibi-
tory effect of flavonoids on Cdks (such as Cdk5) led us to
investigate the functional relationship between inhibition
of Cdk5 and activation of PXR.
We first showed that p35, a critical regulatory protein
for Cdk5, is expressed in the human liver carcinoma cell
line HepG2. We found an inverse correlation between
Cdk5 activity and PXR activity: downregulation of Cdk/
p35 signaling activated whereas its upregulation inhibited
PXR. In addition, flavonoids restored the Cdk5-mediated
downregulation of CYP3A4 promoter activity. We further
showed that Cdk5/p35 directly phosphorylated PXR.
Cdk5, unlike its regulatory subunit p35, is ubiquitously
expressed. The expression of p35 is highest in the ner-
vous system, and has been reported in many non-CNS
Figure 4 Flavonoids and calpeptin decrease the inhibitory effect of Cdk5 on PXR-mediated CYP3A4 promoter activity. (A) HepG2 was tran-
siently co-transfected with FLAG-PXR, CYP3A4-luc, CMV-renilla luciferase (as a transfection control), and either Cdk5 (+ Cdk5) or pcDNA3 vector (-Cdk5) 
plasmids at a ratio of 1:15:1:3, respectively. A total of 20 μg of combined plasmids was used to transfect 5 × 106 cells seeded in a T75 flask 16 h before 
transfection. Transfected cells were seeded into white 96-well plates (at 10,000 cells/well) 24 h later, and treated with DMSO or compounds as indi-
cated for 24 h before Dual-glo luciferase assay. CYP3A4 promoter activity was normalized by using activity of the CMV-renilla, and expressed as fold 
induction over control (DMSO; without Cdk5 transfection). The values represent the average of 8 independent experiments, with the standard devi-
ation denoted as bars. The significance of the difference between datasets was determined by using the Student's t test. (B) Using fold induction over 
control as described in (A), the Cdk5-mediated inhibition of CYP3A4 promoter activity was expressed a percentage of inhibition by Cdk5 [% inhibition 
= 100% × (signal without Cdk5 - signal with Cdk5)/signal without Cdk5)].
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Figure 5 Cdk5 phosphorylates PXR in vitro. Kinase assays were per-
formed as described under Methods. Histone H1 (H1) was the positive 
and GST the negative control. The amount of substrates loaded to 
PAGE (substrate inputs) was illustrated by SimplyBlue staining. M, mo-
lecular weight marker.
Substrate inputs 32P
50kD
Table 1: Apigenin inhibits multiple Cdks.
Kinase Kd (μM)
Cdk2 9.8
Cdk3 > 30
Cdk4 7.0
Cdk5 3.9
Cdk7 1.7
Cdk8 5.8
Cdk9 2.0
Cdk11 3.0Dong et al. BMC Biochemistry 2010, 11:23
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cells and tissues such as lens epithelia [27], muscle tissues
[28] hepatoma cells [25], adipose tissues [29] and male
reproductive system [30]. Our discovery that p35 is
expressed in HepG2 human liver carcinoma cells expands
the list of cells and tissues that are found to express p35.
p35 can be cleaved to generate the highly active p25 and
we show that calpeptin, a peptide previously reported to
inhibit the cleavage of p35 [23,24], highly induced PXR
activity and blocked the inhibitory effect of Cdk5 on
PXR, supporting that Cdk5 negatively regulates PXR
activity.
As with other Cdk inhibitors, the inhibitory effect of
flavonoids is not specific to Cdk5, as suggested by inhibi-
tion of multiple Cdks by apigenin in the Cdk kinase pro-
filing assay. Cdk2 has been previously shown to
negatively regulate PXR function [9]. Our data suggest
that flavonoid-mediated activation of PXR is not because
of the inhibition of Cdk5 only; inhibition of multiple
Cdks, including Cdk2, might contribute to this activation.
Gene expression of CYP3A4 is regulated not only by
PXR but also by other signaling pathways including other
nuclear receptors. These signaling pathways might also
cross-talk with each other . Therefore, it is important to
investigate the regulation of other signaling pathways and
nuclear receptors by flavonoids and the implications in
the regulation of gene expression of CYP3A4 and other
CYPs. It is also possible that metabolites of flavonoids
may play roles in this complex regulation network. Com-
prehensively investigating the signaling network regu-
lated by flavonoids and their metabolites will contribute
to understanding the roles of flavonoids in potential
herbal-drug interactions.
Conclusions
In conclusion, this is the first report that correlates the
effect of flavonoids on regulation of expression of drug-
metabolizing enzymes to their inhibitory effect on Cdks,
which in turn negatively regulates PXR function. Because
of the widespread use of flavonoids by humans as dietary
constituents, our discovery may have important implica-
tions on the pharmacokinetics of drugs co-administered
with herbal remedy and herbal-drug interactions.
Methods
Compounds, antibodies, and other materials
Cell culture reagents were obtained from Invitrogen
(Carlsbad, CA); compounds and anti-β-actin antibody
from Sigma-Aldrich (St. Louis, MO); purified Cdk5-p35
complex and ATP from Millipore (Billerica, MA); puri-
fied human PXR protein from Origene Tech (Rockville,
MD); [γ-32P] ATP from PerkinElmer Life Sciences
(Waltham, MA); charcoal/dextran-treated FBS from
Hyclone (Logan, UT); Bradford reagent from Bio-Rad
(Hercules, CA); and anti-Cdk5 (sc-249) and anti-p35 (sc-
821) antibodies from Santa Cruz Biotechnology (Santa
Cruz, CA).
Cell lines, plasmids and transfection
HepG2 liver carcinoma cells, IMR-32 neuroblastoma
cells, and HEK 293T kidney epithelial cells were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA). All cells were maintained at 37°C in a
humidified atmosphere containing 5% CO2. HepG2 and
HEK293T were maintained in modified Eagle's minimal
essential medium (MEM) from A TCC with 10% FBS, 2
mM L-glutamine and 100 U/ml penicillin/streptomycin.
IMR-32 was maintained in modified Eagle's MEM sup-
plemented with 10% FBS. The Cdk5 expression construct
(Cdk5-HA) was provided by Dr. Sander van den Heuvel
(Addgene plasmid 1872; Addgene, Cambridge, MA).
pCMV-mycP35 was provided by Dr. Li-huei Tsai
(Addgene plasmid 1347). FLAG-PXR and CYP3A4-luc
plasmids were constructed as previously described [9].
Transfections were conducted with FuGENE 6 (Roche
Diagnostics), according to manufacturer's instructions.
PXR transactivation assay
Compounds were added to 384-well plates seeded with
cells in a phenol red-free medium containing 5% char-
coal/dextran-treated FBS and incubated for 24 h at 37°C
before conducting the luciferase assay. The final concen-
tration of DMSO in each well was maintained at 0.1%.
DMSO and 2 μM of rifampicin were used as the negative
and positive control, respectively. Luciferase activities
were detected by using EnVision plate reader (PerkinEl-
mer Life Sciences), as previously reported [9].
PXR binding assay
The time-resolved fluorescence resonance transfer (TR-
FRET) PXR competitive binding assay was performed as
d e s c r i b e d  p r e v i o u s l y  [ 9 ] .  B r i e f l y ,  t h e  a s s a y s  w e r e  p e r -
formed in a volume of 20 μl in 384-well solid black plates
with 5 nM GST-hPXR ligand-binding domain, 40 nM flu-
orescent-labeled hPXR agonist (Fluomore PXR Green), 5
nM terbium-labeled anti-GST antibody, and test com-
pound at different concentrations. The reaction mixture
was incubated at 25°C for 30 min and then fluorescent
emissions of each well were measured at 495 nm and 520
nm, using an excitation filter of 340 nm, a delay time of
100 μs, and an integration time of 200 μs on a PHERAStar
plate reader (BMG Labtech, Durham, NC). The FRET
ratio was calculated by dividing the emission signal at 520
nm by that at 495 nm. DMSO was used as the negative
control (0% relative binding) and 10 μM SR-12813, a
human PXR agonist, as the positive control (100% relative
binding). The data were expressed as relative binding (%)
[relative binding (%) = 100% × (DMSO FRET ratio - Com-
pound FRET ratio)/(DMSO FRET ratio - 10 μM SR12813Dong et al. BMC Biochemistry 2010, 11:23
http://www.biomedcentral.com/1471-2091/11/23
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FRET ratio)]. Curves were generated by using GraphPad
Prism 4.0 (GraphPad Software, La Jolla, CA).
siRNA knockdown
Endogenous Cdk5 was knocked down by using ON-TAR-
GETplus SMARTpool Cdk5 siRNA (L-003239-00;
Thermo Scientific, Chicago, IL). Knockdown efficiency of
the target gene was confirmed by Western blotting, as
described previously [9]. Briefly, HepG2 cells (2 × 105)
were seeded in 6-well plates in serum-free Eagle's MEM.
Cells were transfected with 100 pmol siRNA, using Lipo-
fectamine 2000 (Invitrogen). After 6 h, the medium was
replaced by Eagle's MEM containing 10% FBS and cells
were allowed to grow uninterrupted for 42 h. Cells were
then transfected with a total of 1 μg of plasmid DNA by
using Fugene 6, cultured for another 24 h, and treated
and processed for the luciferase assay or Western blot-
ting.
In vitro Cdk kinase assay
For the in vitro kinase assay, 20 ng of recombinant Cdk5/
p35 was used per reaction. Kinase assays were performed
in 25 μl reactions, with 1 μg substrate protein PXR, 0.5
μmol/l cold ATP and 5 μCi [γ-32P] ATP (6000 Ci/mmol).
GST was expressed and purified by using pGEX-4T-1 in
Escherichia coli BL21 and was used as the negative con-
trol. The reaction mixture was incubated at 30°C for 30
min before being electrophoresed by SDS-PAGE. The gel
was stained by using SimplyBlue SafeStain (Invitrogen),
desiccated by the Labconco gel dryer (Labconco, Kansas
City, MO), and exposed overnight to the Storage Phos-
phor Screen (GE Healthcare). Phosphoimages were
obtained by using the Storm scanner (GE Healthcare). In
vitro  Cdks kinase profiling assays were performed by
Ambit Biosciences (San Diego, CA) as previously
described [38,39].
Statistical analyses
Results are expressed as the mean ± SD of at least three
independent experiments as indicated. The Student's t-
test for the paired samples was used to determine statisti-
cal significance of difference between parameters. Differ-
ences were considered significant for p < 0.05, 0.01 or
0.001 and non-significant for p > 0.05.
Abbreviations
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